Over 75,000 women have chosen MammaPrint to help provide greater clarity on their risk of breast cancer recurrence.

Find out more about MammaPrint and recent developments in breast cancer research.

Join the Symphony Sisterhood on Facebook

MammaPrint test report

MammaPrint provides a clear low risk or high risk result to better predict breast cancer recurrence

MammaPrint High Risk

A high risk result means that a patient has a statistically significant (11.7%) chance that her cancer will recur within 5 years1

View high risk report

MammaPrint Low Risk

A low risk result means that a patient has a statistically significant (1.3%) chance that her cancer will recur within 5 years1

View low risk report

Of physicians had complete or high confidence in their treatment recommendations after receiving the MammaPrint test result, compared to 69% pre-test.2

Recommended by expert medical guidelines

MammaPrint is included in numerous clinical practice guidelines developed by world-recognized cancer care organizations. Clinical guidelines are evidence-based recommendations for healthcare professionals involved in the management of patients.

Guidelines aim to improve the quality of care and services based on the most up to date peer-reviewed evidence. For example, MammaPrint is the only test of its kind endorsed by the American Society of Clinical Oncology for lymph node-positive patients.

Where to next?

I kept thinking maybe I’d made the wrong decision, maybe I should have had a mastectomy. MammaPrint allowed me to calm down, refer back to my results, and return to the faith I had in my treatment. — Mary, a breast cancer survivor

*Randomization is a procedure to allocate clinical study participants into different groups. By using chance to allocate participants, the groups are likely to be similar and allow the effects of the treatments to be compared more fairly.

When patients are recruited to a clinical study and followed forward in time.

A type of clinical trial designed to confirm and expand on the safety and/or effectiveness of an intervention from earlier clinical trials. Phase III trials are often large and may consist of hundreds or even thousands of patients.

REFERENCE

1Drukker, C.A., et al. Int J Cancer. January 2013; 133: 929–936 (RASTER)

2Wuerstlein R, et al. Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIMe Decision Impact Study. Poster presented at San Antonio Breast Cancer Symposium. December 2016; San Antonio, Texas